Literature DB >> 23980793

Altered invariant natural killer T cell subsets and its functions in patients with oral squamous cell carcinoma.

A K Singh1, N K Shukla, S N Das.   

Abstract

Invariant natural killer T (iNKT) cells are glycolipid-reactive T lymphocytes that share receptors and function with natural killer (NK) cells and reportedly play a pivotal role in various immune responses. However, iNKT cells are not well characterized in patients with oral squamous cell carcinoma (OSCC). We investigated the populations and functions of circulating iNKT (CD3(+) 6B11(+) ) cells from thirty-eight patients with OSCC and twenty-eight healthy donors by flow cytometry. Circulating iNKT cells were significantly lower (P < 0.01) in patients as compared to those in healthy controls. Further, iNKT subsets revealed a marked decrease in CD4(-) CD8(-) (double negative, DN) subset with concomitant increase in CD8(+) subset in patients as compared to healthy controls (P = 0.03 and P < 0.01, respectively), whereas CD4(+) subset was similarly distributed in both groups. The functional analysis demonstrated that residual iNKT cells from patients had impaired proliferative response to α-galactosylceramide (α-GalCer)-pulsed dendritic cells (DCs) and Th2-like cytokine profile. However, in vitro activation with α-GalCer-pulsed DCs restores IFN-γ expression and enhances antitumour activity to human cancer cells lines (SCC-4, KB and MCF7). It appears that the selectively enriched iNKT subsets and modulation of their function by specific ligand/agonist may be useful for cellular therapy in patients with OSCC. Further, reduced levels of iNKT cells and its DN subset may be used as potential prognostic factors for patients with OSCC.
© 2013 John Wiley & Sons Ltd.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23980793     DOI: 10.1111/sji.12104

Source DB:  PubMed          Journal:  Scand J Immunol        ISSN: 0300-9475            Impact factor:   3.487


  7 in total

Review 1.  The 'Danse Macabre'-Neutrophils the Interactive Partner Affecting Oral Cancer Outcomes.

Authors:  Sara Hadjigol; Bansari A Shah; Neil M O'Brien-Simpson
Journal:  Front Immunol       Date:  2022-06-16       Impact factor: 8.786

Review 2.  Adoptive Immunotherapy With Engineered iNKT Cells to Target Cancer Cells and the Suppressive Microenvironment.

Authors:  Gloria Delfanti; Paolo Dellabona; Giulia Casorati; Maya Fedeli
Journal:  Front Med (Lausanne)       Date:  2022-05-09

3.  Serial Stimulation of Invariant Natural Killer T Cells with Covalently Stabilized Bispecific T-cell Engagers Generates Antitumor Immunity While Avoiding Anergy.

Authors:  Shalu Sharma Kharkwal; Christopher T Johndrow; Natacha Veerapen; Himanshu Kharkwal; Noemi A Saavedra-Avila; Leandro J Carreño; Samantha Rothberg; Jinghang Zhang; Scott J Garforth; Peter J Jervis; Lianjun Zhang; Alena Donda; Amareeta K Besra; Liam R Cox; Steven C Almo; Alan Howell; Elizabeth E Evans; Maurice Zauderer; Gurdyal S Besra; Steven A Porcelli
Journal:  Cancer Res       Date:  2021-01-22       Impact factor: 13.312

4.  Intracellular IL-4 and IFN-γ expression in iNKT cells from patients with chronic lymphocytic leukemia.

Authors:  Agnieszka Bojarska-Junak; Małgorzata Waldowska; Justyna Woś; Sylwia Chocholska; Iwona Hus; Waldemar Tomczak; Michał Dzik; Marek Hus; Jacek Roliński
Journal:  Oncol Lett       Date:  2017-11-24       Impact factor: 2.967

Review 5.  The Role of Natural Killer T Cells in Cancer-A Phenotypical and Functional Approach.

Authors:  Daniëlle Krijgsman; Marianne Hokland; Peter J K Kuppen
Journal:  Front Immunol       Date:  2018-02-27       Impact factor: 7.561

6.  Expansion of highly activated invariant natural killer T cells with altered phenotype in acute dengue infection.

Authors:  A Kamaladasa; N Wickramasinghe; T N Adikari; L Gomes; N L A Shyamali; M Salio; V Cerundolo; G S Ogg; G Neelika Malavige
Journal:  Clin Exp Immunol       Date:  2016-08       Impact factor: 4.330

7.  Blood biomarkers associated to complete pathological response on NSCLC patients treated with neoadjuvant chemoimmunotherapy included in NADIM clinical trial.

Authors:  Raquel Laza-Briviesca; Alberto Cruz-Bermúdez; Ernest Nadal; Amelia Insa; María Del Rosario García-Campelo; Gerardo Huidobro; Manuel Dómine; Margarita Majem; Delvys Rodríguez-Abreu; Alex Martínez-Martí; Javier De Castro Carpeño; Manuel Cobo; Guillermo López Vivanco; Edel Del Barco; Reyes Bernabé Caro; Nuria Viñolas; Isidoro Barneto Aranda; Santiago Viteri; Bartomeu Massuti; Marta Casarrubios; Belén Sierra-Rodero; Carlos Tarín; Aránzazu García-Grande; Cara Haymaker; Ignacio I Wistuba; Atocha Romero; Fernando Franco; Mariano Provencio
Journal:  Clin Transl Med       Date:  2021-07
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.